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Mast cell chemotaxis is essential for cell recruitment to target tissues, where these
cells play an important role in adaptive and innate immunity. Stem cell factor (SCF) is
a major chemoattractant for mast cells. SCF binds to the KIT receptor, thereby triggering
tyrosine phosphorylation in the cytoplasmic domain and resulting in docking sites for
SH2 domain-containing molecules, such as Lyn and Fyn, and the subsequent activation
of the small GTPases Rac that are responsible for cytoskeletal reorganization and mast
cell migration. In previous works we have reported the role of 3BP2, an adaptor molecule,
in mast cells. 3BP2 silencing reduces FcεRI-dependent degranulation, by targeting Lyn
and Syk phosphorylation, as well as SCF-dependent cell survival. This study examines
its role in SCF-dependent migration and reveals that 3BP2 silencing in human mast cell
line (LAD2) impairs cell migration due to SCF and IgE. In that context we found that
3BP2 silencing decreases Rac-2 and Cdc42 GTPase activity. Furthermore, we identified
Myo1f, an unconventional type-I myosin, as a new partner for 3BP2. This protein,
whose functions have been described as critical for neutrophil migration, remained
elusive in mast cells. Myo1f is expressed in mast cells and colocalizes with cortical
actin ring. Interestingly, Myo1f-3BP2 interaction is modulated by KIT signaling. Moreover,
SCF dependent adhesion and migration through fibronectin is decreased after Myo1f
silencing. Furthermore, Myo1f silencing leads to downregulation of β1 and β7 integrins
on the mast cell membrane. Overall, Myo1f is a new 3BP2 ligand that connects the
adaptor to actin cytoskeleton and both molecules are involved in SCF dependent mast
cell migration.
Keywords: adaptor molecules, unconventional myosins, KIT signaling, mast cells, cell migration and adhesion,
cytoske leton
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INTRODUCTION
Mast cell recruitment into connective tissue in a healthy or
pathological situation requires cell adhesion, spreading and
migration, and these events are transduced from external stimuli
to cytoskeleton rearrangements. Most established mast cell
chemoattractants are antigens recognized by immunoglobulins
bound to FcεRI and stem cell factor (SCF), the ligand for
the KIT receptor, a type III tyrosine kinase receptor (1). KIT
signal transduction is crucial for mast cell growth, survival and
differentiation, as well as for the migration and homing of
mast cells into target tissues. KIT through PI3 kinase signaling
influences mast cell growth and survival (2). SCF is a major
chemotactic attractant for mast cells and their precursors.
Once bound to KIT, SCF causes KIT tyrosine phosphorylation
and formation of docking sites for SH2 domain-containing
molecules, such as Lyn and Fyn. Activation of Fyn leads to
phosphorylation of Gab2 and subsequent activation of the small
GTPase Rac that is responsible for the cytoskeletal reorganization
and mast cell migration (3).
The SH3-binding protein 2 (3BP2) is a cytoplasmic adapter
protein originally identified to bind to the tyrosine kinase Abl
SH3 domain (4). Human 3BP2 is a 561-aa protein containing
an N-terminal pleckstrin homology (PH) domain, an SH3-
binding proline-rich region, and a C-terminal SH2 domain.
3BP2 positively regulates mast cell responses through FcεRI
and KIT receptors (5, 6). The knockdown expression of 3BP2
reduces degranulation, cytokine secretion and mast cell survival
(5, 6). It has been reported that 3BP2 is required for optimal
activation of Src family kinases and small GTPase Rac2 that
regulates chemoattractant-mediated neutrophil activation, and
motility. Consequently, the loss of 3BP2 increases susceptibility
to infections such as Listeria monocytogenes. These functional
defects are partially explained by the failure to fully activate Vav1
(7). Vav1 is a guanosine-nucleotide-exchange factor (GEF) for
members of the Rho GTPase family (8). RhoA, Rac1,2,3, and
Cdc42 belong to the family of Rho GTPases that regulates a range
of biological response pathways, including cell motility and actin
dynamics (9).
This work aims to investigate the role of 3BP2 in cytoskeleton
reorganization and mast cell migration. In order to shed light on
the molecules involved in 3BP2 signalosome, the three-hybrid
screening system was performed on a bone marrow expression
library using human 3BP2 as bait. Vav1 andMyo1f were found to
be ligand partners for 3BP2. Vav1 has previously been reported
to bind to Y183 3BP2 (10), but Myo1f represents a novel binding
ligand for 3BP2 and its expression and function in mast cells
remain elusive.
Myo1f is a long-tailed unconventional class I myosin whose
gene is located on the chromosome 19 (19p13.3-p13.2) (11).
Myosins are actin-dependent molecular motors that use the
energy from ATP hydrolysis to move along actin filaments
(12). Class I myosins are evolutionarily ancient, represent the
largest group of unconventional myosins and exist in a wide
range of species. Mice and humans have a total of eight class I
myosin heavy-chain genes, six of which encode short-tailed forms
(Myo1a, b, c, d, g and h) and two of which encode long-tailed
(amoeboid) forms (Myo1e and f). All class I myosins consist
of an N-terminal motor domain, light-chain-binding IQ motifs
(calmodulin binding) and a basic tail homology 1 (TH1) domain
thought to affect interactions withmembranes. Long-tailed class I
myosins have an additional proline-rich TH2 domain and a TH3
domain containing a single Src homology 3 (SH3) domain (11).
The Myo1f transcript has been described as selectively expressed
in the spleen, mesenteric lymph nodes, thymus, lung, NK cells,
macrophages, and dendritic cells (13).
Interestingly, Myo1f knockout mice have also been reported
to show increased susceptibility to infection by Listeria
monocytogenes as a consequence of abnormally increased
adhesion and reduced motility of neutrophils. This increased
adhesion results from augmented exocytosis of β2 integrin-
containing granules (14).
This study examines the capacity of 3BP2 to regulate Rho
GTPase activity and mast cell migration and identifies Myo1f as
a binding partner for 3BP2. Further, it characterizes Myo1f
expression and distribution in mast cells and evaluates Myo1f
function in adhesion, integrin expression, and SCF dependent
migration in mast cells.
MATERIALS AND METHODS
Cell Lines and Reagents
The LAD2 huMC line kindly provided by Drs. A. Kirshenbaum
and D.D. Metcalfe (National Institutes of Health, Bethesda, MD)
was grown in StemPro-34 media (Life Technologies, Carlsbad,
CA), supplemented with StemPro-34 nutrient and L-glutamine
(2mM), penicillin (100 U/mL) and streptomycin (100µg/mL),
and 100 ng/mL SCF (Amgen, Thousand Oaks, CA) (15). The
human mast cell line HMC-1 was obtained from J.H. Butterfield
(Mayo Clinic, Rochester, MN, USA) and was grown in Iscove’s
medium supplemented with 10% heat-inactivated FBS, penicillin
(100 U/ml), and streptomycin (100µg/ml) (16). COS-7 cell line
was cultured in Dulbecco’s Modified Eagle Medium (DMEM),
10% FCS, 1% penicillin-streptomicin (mixture 5k/5k), 1% L-
glutamine A 200 mM.
Antibodies and Other Reagents
Mouse antibodies, α-3BP2 C5, α-3BP2 C11, α-Myo1f C5, α-KIT
(clone Ab81), and rabbit α-Kit (H300) were purchased from
Santa Cruz (Santa Cruz Biotechnology, Inc. Santa Cruz, CA).
Mouse anti-CD29-APC (α-integrin β1) clone MAR4 from BD
Pharmigen (BD Biosciences, San José, CA), mouse α-integrin
β7-PE from Biolegend (San Diego, CA), goat α-mouse alexa-
647, and goat α-rabbit alexa-488 were from Life Technologies
(Carlsbad, CA), mouse α-human-FcεRI-PE from eBioscience
(San Diego, CA). Mouse α-Rac1, α-RhoA, and α-Cdc42
antibodies were from Cytoskeleton (Cytoskeleton Inc., Denver,
CO), mouse α-Rac2 antibody was from antibodies-online.
Antiphosphotyrosine (pTyr) monoclonal was obtained from
Zymed Laboratories (Invitrogen Life Technologies, Carlsbad,
CA). Biotinylated human IgE (IgEB) was obtained from
Abbiotec (San Diego, CA, USA). Anti-mouse peroxidase Ab
was obtained from DAKO (Carpinteria, CA, USA). Streptavidin,
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the tyrosine kinase inhibitor sunitinib malate, puromycin, poly-
lysine-D, fibronectin, doxycycline hyclate, mouse α-tubulin
(DM1A), and mouse α-flag (m2Ab) were purchased from
Sigma (Sigma-Aldrich, St. Louis, MO, USA). α-pKIT Tyr703
was from Cell Signaling (Cell Signaling Technology, Danvers,
MA) and α-GPF from Roche (Roche Molecular Biochemical,
Pleasanton, CA). Goat α-rabbit-HRP was from Life Technologies
(Life Technologies).
Cell Activation or Inhibition
Cells were starved overnight in culture media without SCF.
The following day, cells were stimulated with 100 ng/ml of
SCF in Tyrode’s buffer for the indicated times. For IgE-
dependent activation we sensitized cells with biotinylated IgE
(0.1µg/ml) overnight, and stimulated them for 30min at 37◦C
with streptavidin (0.4µg/ml) to induce IgE crosslinking. For
inhibition, cells were incubated with Sunitinib for 30min at 37◦C
in Tyrode’s Buffer, DMSO was used as a control.
Immunofluorescence Assays
Cells were activated or inhibited as described above. Afterwards,
cells were fixed in PFA 4%—phosphate buffered saline (PBS) at
4◦C. Then, cells were seeded on a poly-lysine-D coated plate with
a Cytospin device (50.000 cells/sample). Cells were permeabilized
with Saponin buffer (PBS-0.05% Saponin) for 15min at 4◦C.
Afterwards, we used blocking buffer [0.2% skimmed milk, 2%
FCS, 1% bovine serum albumin (BSA), 0.01% triton X-100, 0.01%
NaN3, 20% Rabbit Serum (or 20% FCS), dissolved in PBS] for
1 h at 4◦C. We used primary antibodies (0.1–0.2 µg/100.000 cell)
for 2 h of incubation at 4◦C. At last, we used goat anti-mouse or
goat anti-rabbit secondary antibodies labeled with Alexa-488 or
Alexa-647 for 45min (dilution 1:300 – 1:500) at 4◦C. For nuclei
staining we used Hoechst stain (dilution 1:10.000 in PBS-0.1%
BSA), and for actin staining we used phalloidin-TRITC (dilution
1:500 – 1:1000). Preparations were visualized with a Leica SP5
confocal microscope. All images were processed with Fiji/ImageJ
free software (17).
Yeast Three-Hybrid Assay
The yeast three-hybrid system was performed as described
elsewhere (18). The 3BP2 adaptor cloned in the bicistronic
pBridge vector (which carries the src-Fyn clone) and transformed
in the yeast strain CG1945 was used as a bait to screen a
human bone marrow matchmaker cDNA library cloned in
pACT2 (Clontech Laboratories Inc, Mountain View, CA, USA).
Cotransformed clones that grew under restrictive conditions
were then tested using the β-galactosidase assay. The β-
galactosidase liquid culture assay using o-nitrophenyl β-D-
galactopyranoside as a substrate was carried out as described
in the Clontech yeast protocols handbook. Positive clones were
processed to purify their plasmids and they were sequenced.
Active GTPase Assays
GTPase activation assays were performed using Rac1, Cdc42,
and RhoA G-LISA kits following manufacturer’s instructions
(Cytoskeleton) as well as described elsewhere (19). Briefly, Cell
lysates (5 × 105 to 2 × 106 cells) were prepared using G-LISA
lysis buffer, snap-frozen in liquid nitrogen and processed within 2
weeks after preparation. Lysate aliquots, corresponding to Rac1-
Rac2, Cdc42, and RhoA assays, were applied, respectively, to
wells coated with Rac1, Cdc42, or Rho-GTP-binding protein.
Active, GTP-bound GTPases bound to the wells were detected
with the corresponding specific Ab. Constitutively active proteins
were used as a standard.
Immunoprecipitation, Immunoblotting, and
COS Transfection
Cells were treated with Sunitinib as described above. Whole
cell lysate preparations were obtained as described elsewhere
(20). Immunoprecipitation experiments were conducted using a
procedure described elsewhere (5). COS-7 cells were transiently
transfected using Nucleofector (Cell Line Nucleofector Kit V
from Lonza Cologne AG, Lonza) following the manufacturer’s
instructions. Cells were transfected with a flag-tagged Myo1f
construct from (OriGene Technologies, Rockville, MD), cloned
into a pCMV6-Entry plasmid. 3BP2 cloned in pCDNA 3.1 and
Fyn cloned in psrα used in COS transfections were described
in Saborit et al. (21) and Alvarez-Errico et al. (22), respectively.
SH2-3BP2-GFP construct was obtained cloning the SH2 domain
of 3BP2 into a pN3-EGFP construct (Clontech Laboratories,
Inc, Mountain View, CA, USA); pN3-EGFP plasmid was used
as control.
Lentiviral Transduction
Lentiviral particles to silence the 3BP2 gene expression were
generated using Mission shRNA technology, according to the
manufacturer’s instructions (Sigma-Aldrich, St. Louis, MO) as
described elsewhere (5, 6). The lentivirus with shRNA sequences
A, B, C, or D for Myo1f were from Origen Technologies. The
TRCN0000158118 sequence that overlaps with sequence D in
the Origen plasmids (CGTCTTCAAGACCGAGTTTGT) was
furthered cloned into a Tet-pLKO-puro plasmid [Addgene
plasmid 21915; (23)] which expression is inducible by
doxycycline (0.5µg/mL) and used for subsequent experiments.
The Lenti ORF clone of human SH3-domain binding protein
2 (SH3BP2), transcript variant 1, mGFP tagged and Lenti vector
with C-terminal monomeric GFP tag as a control (OriGene
Technologies) were used for 3BP2 overexpression experiments.
Migration Assays
Migration assays were performed using transwell polycarbonate
membranes from Costar (8µm pores, Corning Incorporated,
Kennebunk, ME) suitable for mast cells as reported in Kataoka
et al. (24). Briefly, LAD2 cells were starved O/N in complete
media without SCF and, when necessary, with biotinylated IgE.
The next day, 1 × 105 cells per point were washed with fresh
StemPro-34 media and dropped into the upper transwells. After
10min for stabilization we added the stimulus on the bottom
well (100 ng/mL of SCF, 0.4µg/ml streptavidin or StemPro
Supplement 1x), and the cells were left to migrate for 4 h at 37◦C
and 5% CO2. After 4 h the cells were rinsed with an EDTA-NaCl-
PBS buffer to detach them from the bottom of the upper chamber,
they were stained with crystal violet and counted under optic
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microscopy. In all cases, the cells in the upper chamber were
counted after 4 h with Trypan blue to evaluate viability.
Adhesion Assays
P96 plates were coated O/N with fibronectin (20µg/mL), poly-
lysine-D (0.1% w/v) or PBS. Next day, wells were washed with
PBS, blocked with 5% BSA and washed again with PBS. 1–5
× 104 cells starved O/N were dropped in triplicate wells and
activated with 100 ng/mL SCF in complement-free StemPro-34
media for 30min. After that, wells were rinsed 3 times with PBS
and the number of remaining cells was assessed with CellTiter-
Glo R© Luminescent Cell Viability Assay from Promega (Promega
Corporation, Madison, WI).
FACS Staining
β7 and β1 integrins, KIT and FcεRI expression were detected
by direct staining with the indicated Abs for 30min at 4◦C.
Cells were then analyzed using a FACSCalibur flow cytometer
(FACScan; BD Biosciences). In all cases dead cells were excluded
based on their Forward (FSC) and side scattering (SSC) profile.
Data Analysis
All results are expressed as mean ± standard error of the mean
(SEM). Unpaired student’s t-test or one-way ANOVA were used
to determine significant differences (p-value) between two or
several experimental groups, respectively, after determination of
normal distribution of the sample and variance analysis.
RESULTS
3BP2 Is Critical for SCF-Dependent Mast
Cell Migration
Given that 3BP2 is required for proper KIT signaling (6), and
SCF, the ligand for KIT, is a major chemotactic factor in mast
cells (1), this study explores the capacity of 3BP2 to modulate
SCF-dependent chemokinesis. Migration assays were carried out
using Transwell chambers, with SCF as the stimuli. 3BP2 shRNAs
sequences were validated in previous works (5, 6). Our data
show that 3BP2-silenced LAD2 cells (Figure 1A) do not migrate
toward an SCF gradient (Figure 1B). As described previously,
3BP2 knockdown cells downregulate KIT expression, thereby
leading to cell apoptosis (6). The migration experiments were
performed under the same conditions in which cell survival
and KIT expression were not significantly affected (first week
of transduction). The viability was tested in all these conditions
to rule out a lack of migration due to cell apoptosis (data not
shown). To ensure the specificity of this event, silenced cells
were reconstituted for 3BP2 using a plasmid-encoding 3BP2-GFP
protein or a control GFP protein (Figure 1C). The GFP and KIT
expression levels were monitored to ensure good transfection
efficiency before themigration tests were carried out (Figure 1D).
As expected, 3BP2 reconstitution reestablished the capacity for
cell migration (Figure 1E).
Next, we analyzed whether 3BP2 was also needed for mutant
KIT D816V-mediated migration. KIT D816V is a hallmark of
mastocytosis, a rare disease caused by the accumulation of
functionally defective mast cells. For that we used HMC-1 cell
line in which KIT has the gain-of-function mutation D816V.
As shown in Figure 2, 3BP2 silencing impairs cell migration
toward SCF in HMC-1 cells. In this case migration basal levels
are higher than those observed in LAD2 mast cells since KIT
signaling is constitutively active. Although the mutation confers
receptor activation in absence of SCF, SCF addition still increases
cell activation as reported by us and others (6, 25). Altogether
our data indicates that 3BP2 provides signals needed for SCF-
dependent mast cell migration.
3BP2 Is Essential for FcεRI-Mediated Mast
Cell Migration
It has been reported that Lyn and Syk are essential for FcεRI-
mediated migration (26). Since the adaptor molecule 3BP2
coprecipitates with Lyn and Syk in mast cells and 3BP2 silencing
leads to a decrease in Syk phosphorylation (5) we next assessed
the ability of 3BP2 to promote FcεRI-mediated migration. For
that purpose non target or 3BP2 silenced LAD2 cells were
sensitized with biotinylated IgE overnight. Migration assays were
performed using streptavidin as stimuli (mimicking the allergen).
As shown in Figure 3, 3BP2 silencing leads to an impairment
in migration toward the streptavidin. Levels of FcεRI in both
types of cells were similar. As reported previously, 3BP2 silencing
does not affect FcεRI expression levels (5). To check whether
3BP2 role in chemotaxis goes beyond FcεRI or KIT receptors we
carried out migration assays using the StemPro 34 supplement as
stimuli. This supplement contains a wide array of growth factors
needed for growth and proliferation of LAD2 cells. Interestingly,
cells where 3BP2 was silenced show less migration toward the
stimuli suggesting an overall role of 3BP2 in LAD2 migration
(Figure S1).
The 3BP2 Adaptor Protein Is Required for
Rac2 and Cdc42 Activation in Mast Cells
The adaptor molecule 3BP2 has been proposed as a key
molecule for Rho family GTPase activation and migration in
neutrophils (7). The Rho family of GTPases undergoes activation
by GTP/GDP exchange and controls cytoskeletal rearrangements
(9). First we characterized the activation pattern of the Rho
GTPase family in the human mast cell line LAD2 (Figure S2).
Activation of Rac1, Rac2, and Cdc42 increases after IgE and SCF
stimulation. Thus, we then performed an assay to determine
RhoA/Rac1/Rac2/Cdc42 activity in 3BP2-silenced LAD2. Our
results show that Cdc42 and Rac2 activation was significantly
impaired in 3BP2-silenced cells after activation. Interestingly,
Rac-1 was not modified, thus indicating that 3BP2 is selectively
relevant for activation of some members of Rho family GTPases
(Figure 4). The data suggest the involvement of 3BP2 in
pathways associated with cell motility and actin dynamics.
Myo1f as a Novel Ligand for 3BP2
In parallel to these studies, we screened a human bone marrow
library using the yeast three-hybrid system used previously (18,
21), this time with 3BP2 as the bait in order to search for
new ligands for 3BP2. Our screening process rendered known
partners for 3BP2, including Vav1 (data not shown) and Myo1f,
a novel ligand. Myo1f is a long-tailed class I myosin that consists
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FIGURE 1 | 3BP2 knockdown impairs SCF-dependent mast cell migration. (A) Western blot showing the 3BP2 shRNA knockdown in LAD2 cells. (B) Percentage of
migrated non-target control (NT-shRNA) o 3BP2-knockdown (3BP2-shRNA) LAD2 mast cells toward SCF gradient (100 ng/mL). (C) Western blot determination of the
reconstitution of both groups with 3BP2-GFP or GFP alone. (D) GFP and KIT receptor expression determined by flow cytometry. NT-shRNA is represented by an
empty black curve and 3BP2-shRNA is represented by a filled gray curve. Mean intensity of fluorescence (MIF) of each group is represented in parentheses. (E)
Percentage of cell migration after 4 h chemotaxis with SCF (100 ng/mL) of silenced and reconstituted cells, as indicated in the figure. Viability was tested in the upper
wells after the assay. The one-way ANOVA test was used for the statistical analysis (*p < 0.05, ***p < 0.001). Migration data are the mean of three independent
experiments.
FIGURE 2 | 3BP2 knockdown decreases migration of mast cells harboring the KITD816V mutation. (A) Western blot showing the 3BP2 shRNAs knockdown
in HMC-1 cells. (B) Percentage of migrated HMC-1 mast cells silenced for 3BP2 (3BP2-shRNA) or non-target control (NT-shRNA) toward an SCF gradient
(100 ng/mL). The student’s t-test was used for the statistical analysis (*p < 0.05, ****p < 0.0001). In all migration assays, viability was tested in the upper wells after
the assay. Data are the mean of three independent experiments.
of an N-terminal motor domain, light-chain-binding IQ motifs,
a basic tail homology 1, a proline-rich TH2 domain and a TH3
domain containing a single Src homology 3 (SH3) domain.
A positive clone observed in the screening process encoded
the c-terminal region of the protein containing the complete
SH3 domain (Figure 5A). Moreover, 3BP2 coprecipitated with
Myo1f in transfected COS cells in the absence or presence of
Fyn kinase (Figure 5B), thereby indicating an interaction that is
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FIGURE 3 | 3BP2 also reduces significantly IgE-dependent cell migration. (A) FcεRI expression in NT and 3BP2-silenced LAD2 cells. (B) Percentage of cell migration
after 4 h chemotaxis with IgE+ Streptavidin in NT and 3BP2-silenced cells. Viability was tested in the upper wells after the assay. The one-way ANOVA test was used
for the statistical analysis (***p < 0.001). Migration data are the mean of three independent experiments.
FIGURE 4 | 3BP2 knockdown impairs Cdc42 and Rac2 activation in mast cells. G-Lisa quantification of GTP-bound (active) small GTPases Rho (A) Cdc42; (B) Rac2,
(C) Rac1, and (D) RhoA were performed before and after activation by IgE-stv plus SCF for 30min in LAD2 cells. (E) Western blot showing GTPases levels in NT and
3BP2-silenced cells. The one-way ANOVA test was used for the statistical analysis (**p < 0.01, ****p < 0.0001). Data are the mean of three independent experiments.
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independent of phosphorylation. Interestingly, Myo1f and 3BP2
are susceptible to phosphorylation by Fyn kinase, thus suggesting
regulation of these proteins upon phosphorylation. In order to
check whether Myo1f can also be recruited by the SH2 domain
of 3BP2, we performed an immunoprecipitation experiment in
COS cells transfected with only the SH2 domain of 3BP2 in
the presence of Fyn. Our findings revealed that no binding was
observed in these conditions (Figure 5C).
Myo1f Is Expressed in Mast Cells and
Colocalizes With 3BP2
Next, we determined the expression of Myo1f in human mast
cells. Mast cell lines LAD2 and HMC-1 and CD34+-derived
human mast cells express Myo1f, as confirmed by western blot in
our study (Figure 6A). Myo1f colocalizes with the cortical actin
network in resting conditions and after SCF stimulation in LAD2
cells (Figure 6B). Myo1f and 3BP2 showed some localization
under resting and SCF-activated conditions. Interestingly, Myo1f
and 3BP2 colocalization was found mostly on the cell membrane
at 5min (Figure 6C). Our data suggest that KIT activation may
modulate the 3BP2-Myo1f interaction. In that context, in HMC-
1 cell line, where KIT is constitutively active, 3BP2 and Myo1f
colocalized at the plasmamembrane. Remarkably, the KIT kinase
inhibition with sunitinib altered the colocalization (Figure 6D)
and 3BP2-Myo1f coprecipitation is abrogated in those conditions
(Figure 6E). These data indicate that KIT signaling can regulate
the Myo1f-3BP2 interaction.
Myo1f Knockdown Does Not Impair
SCF-Dependent Mast Cell Migration
We next assessed whether Myo1f knockdown can modulate KIT
functions by analyzing cell migration. Various Myo1f shRNA
sequences were tested in LAD2 cells (Figure 7A). Only one
shRNA sequence showed significant Myo1f silencing and was
further cloned under doxycycline-inducible plasmid to control
Myo1f silencing and reconstitution at will. Western blot was
performed to corroborate the knockdown data (Figure 7B), and
KIT expression levels were evaluated by flow cytometry in non-
target cells vs. Myo1f-silenced cells (Figure 7C). Our results show
that Myo1f knockdown does not affect the capacity of mast
cells to migrate toward SCF under these conditions (Figure 7D).
Viability was also monitored after migration and showed no
changes (data not shown).
β1 (CD29) and β7 Integrin Expression Are
Affected in Myo1f and 3BP2 Silencing
It has been reported that neutrophils from Myo1f-deficient mice
exhibit abnormally increased adhesion and reduced motility
as a result of augmented exocytosis of β2-integrin–containing
granules and a reduction in cortical actin (14). β1 and β7 integrins
are responsible for migration and homing in SCF-dependent
mast cell migration (27). Thus, we analyzed the integrin profile
of β1 (CD29), β2 (CD18), and β7 chains in Myo1f vs. control
cells. β2 expression was very low in mast cells under various
treatments, and no differences were observed in silenced or
control cells (data not shown). Conversely, β1 and β7 integrins
were well expressed in mast cells, and no significant differences
were observed between untreated and SCF-stimulated cells in
terms of membrane expression measured by flow cytometry
(data not shown). Interestingly, Myo1f-silenced cells were found
to express significantly less β1 integrin, in comparison with
non-target cells (Figure 8A). Our results also show mild but
significant differences in β7 expression between control cells and
Myo1f-silenced cells (Figure 8B).
SCF-dependent mast cell migration is preceded by an increase
in cell adhesion, a process that is dependent on integrins (28).
Next we assessed whether the differential expression of integrins
on Myo1f silencing affects SCF-dependent cell adhesion. As
shown in Figure 8C, Myo1f silencing induced by doxycycline
affected SCF-induced adhesion to fibronectin.
Finally, we measured the capacity of these cells to migrate
toward an SCF chemotactic gradient through a fibronectin-
coated surface. Our data show that Myo1f-silenced cells had a
significantly lower migration capacity under these conditions,
thus indicating that this impaired adhesion affected mast cell
migration (Figure 8D).
We conducted similar experiments in 3BP2 silencing cells
assessing integrins expression profile. We found that β1 integrin
expression was significantly reduced but β7 integrin expression
was unaffected in 3BP2-silenced cells (Figures 9A,B). We found
as well significant differences in cell adhesion to fibronectin
in 3BP2-silenced cells (Figure 9C). These differences may also
contribute to the capability of cells to migrate. As we show
above when 3BP2 expression is low or almost absent cell
migration is more grossly affected that the one observed in
Myo1f-silenced cells.
DISCUSSION
Migration of mast cells is required for their recruitment to
target tissues and for their infiltration to inflammation sites
associated with chronic atopic diseases, or during bacterial or
parasitic infection. Thus, mast cells recognize chemotactic stimuli
and trigger a signaling cascade of events that lead to integrin
activation, adhesion and migration. SCF, the KIT ligand, is a
key chemotactic factor and is crucial for mast cell proliferation,
survival, homing andmigration. Proper KIT signaling is required
to ensure that these events progress properly. Some years ago,
our group showed that the 3BP2 adaptor protein previously
described as critical for mast cell degranulation through FcεRI
(5) also regulates survival through KIT receptor expression and
signaling (6). As we reported, 3BP2 regulates KIT transcription
through microphthalmia-associated transcription factor (MITF),
described to control KIT expression. Thus, reduced 3BP2
expression is associated with decreased KIT expression and
increased cellular apoptosis (6).
In this study we show that 3BP2 also plays a role in SCF-
dependent cell migration. Since the silencing of 3BP2 ends up
reducing KIT expression and compromising cell viability, all
experiments we performed were monitored for KIT expression
and cell viability. The mechanisms underlying 3BP2-modulated
cell migration may be related to its role as a scaffold protein,
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FIGURE 5 | Myo1f, a new ligand for 3BP2. (A) Representation of Myo1f. The clone identified through the three-hybrid assay was the SH3 region of this protein
(aa901-1098). (B) Immunoprecipitation of the 3BP2 protein in COS-7 cells transfected with 3BP2 and Myo1f-flag, with or without the presence of Fyn kinase.
Membrane was blotted with α-pTyr, α-flag, and α-3BP2 antibodies. (C) Immunoprecipitation of 3BP2 in COS-7 cells transfected with the SH2 domain of 3BP2
(SH2-GFP) and Myo1f-flag, with or without the presence of Fyn kinase. Membrane was blotted with α-flag and α-GFP antibodies.
since with its binding partners it builds a molecular network that
contributes to the KIT signalosome. Indeed, the silencing of 3BP2
reduces PI3K and MAP kinase signaling after SCF engagement
(6). This work used the yeast three-hybrid system to screen a
human bone marrow library, using human 3BP2 as bait, and
identified Vav1 (clone encoding the SH2 domain; amino acids
665-754) and Myo1f (clone encoding SH3 domain; amino acids
901-1185) as ligands for 3BP2. Vav1 has been reported to bind to
3BP2 in a phosphorylation-dependent manner, thus increasing
NK cell killing (10, 21, 29) and B cell activation (30). 3BP2 has
been reported as crucial for full activation of Vav1 in neutrophils,
thereby supporting a role for the adaptor in neutrophil activation
and migration through activation of Rho family of GTPases (7).
Rho GTPases, specifically Rac1,2,3, RhoA and Cdc42, have been
shown to regulate various exocytosis-related events, including
actin remodeling, exocytic complex formation and calcium
influx, across a number of cell models (31). Although their exact
mechanism of regulation may vary between cells, it appears that
Rho GTPases are predominantly responsible for regulating actin
remodeling. Rac1 and Cdc42 have been reported to stimulate
mast cell exocytosis, while RhoA has no effect (32). Although
Rac1 and Rac2 are 92% identical, they have been shown to have
distinct cellular functions (33). Therefore, a lack of Rac2 results
in diminished chemotaxis and degranulation in mast cells, thus
defining distinct functions for Rac2 that cannot be compensated
for by Rac1 (34, 35). This is consistent with previous data where
we reported that 3BP2 silencing expression inhibits mast cell
degranulation (5) and with the present data, which showed that
Rac2 and Cdc42 activation was impaired in 3BP2 knockdown
mast cells in which chemotaxis was diminished. Interestingly,
Rac2 knockout exhibits a reduction in mast cell survival (34)
as occurs in 3BP2 silenced cells (6), thus suggesting that both
molecules are involved in a common signal pathway.
The mechanism used for 3BP2 to connect KIT triggering with
small GTPase activity has not been elucidated. 3BP2 is known to
coprecipitate with KIT in mast cells but no direct binding to the
receptor has been reported (6). Src kinases Lyn, Fyn and PI3K are
ligands for KIT binding to Y568, Y570, and Y721, respectively, in
the cytoplasmic tail of the human receptor. On the other hand,
3BP2 can be phosphorylated by Fyn and Lyn (30, 36) and has
been reported to be associated with Src kinases (5, 36) and PI3K
(29). It is therefore conceivable that KIT and 3BP2 are linked
through these common partners. Interestingly, Fyn-dependent
axis on KIT activation leads to the phosphorylation of Gab2 and
cytoskeleton reorganization and mast cell migration through Rac
GTPase activation (37–40). Studies with different murine KIT
mutants showed the importance of Y567 and Y719 for KIT–
mediated chemotaxis. Phosphorylated Y567 recruits Src kinases
Lyn or Fyn, and this results in activation of the p38 pathway,
which is also important for chemotaxis (39, 41). Interestingly,
3BP2 silencing impairs the p38 pathway in mast cells after FcεRI
triggering (5). Altogether, 3BP2 could act synergistically with
Scr kinases, thus increasing the Rho family of small GTPases
and chemotaxis. In contrast, phosphorylated Y179 recruits PI3K
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FIGURE 6 | 3BP2 and Myo1f colocalization is modulated by KIT signaling in mast cells. (A) Expression of Myo1f in the mast cell lines HMC-1 and LAD2 and in
CD34+-derived human mast cells (huMCs). (B) Immunofluorescence of LAD2 mast cells showing Myo1f (green), actin staining (phalloidin; red) and the nucleus
(Hoechst; blue) after 5min of stimulation with SCF (100 ng/mL) or resting (0min). (C) Immunofluorescence of LAD2 mast cells showing Myo1f (green), 3BP2 (red) and
the nucleus (Hoechst; blue) after stimulation for different times with SCF (100 ng/mL) or resting (0min). (D) Immunofluorescence of HMC-1 cells treated with sunitinib
(10µM) or untreated showing Myo1f (green), 3BP2 (red) and the nucleus (Hoechst; blue). (E) Immunoprecipitation of 3BP2 in HMC-1 cells treated with sunitinib
(10µM) or control (DMSO). Membrane was blotted with α-Myo1f, α-3BP2, and α-KIT/α-pKIT antibodies to check KIT inhibition by sunitinib.
and the mediated and enhanced calcium signaling that has been
found to be critical for chemotaxis (41). 3BP2 silencing has
been reported to impair calcium signaling in mast cells (5). In
summary, 3BP2, through common ligands, may modulate SCF-
dependent MAP kinase activity and calcium influx that leads to
activity of the Rho family of small GTPases, which is important
for mast cell chemotaxis.
In this work, we identified Myo1f as a novel binding partner
for 3BP2. Myo1f is an unconventional long-tailed myosin
not involved in muscle contraction and whose expression is
restricted to the immune system. However, its expression and
role in mast cell function remains unclear. We showed that
Myo1f is expressed in CD34-derived mast cells and mast cell
lines, and colocalizes with the cortical actin ring. 3BP2-Myo1f
interaction is independent of phosphorylation and possibly
involves the SH3 domain of Myo1f and the proline-rich
domain of 3BP2. However, it may be modulated after KIT
activation. After 5min of SCF stimulation, 3BP2 translocates
to the membrane, thereby increasing its colocalization with
Myo1f in that area. Myo1f membrane location is also
more apparent after KIT engagement. This is consistent
with an increase in PI3K activity upon KIT activation and
production of phosphatidylinositol-3, 4, 5-triphosphate (PIP3), a
binding site for PH-domain containing proteins like 3BP2 and
Myo1f. In the HMC-1 mast cell line (harboring KITD816V),
where KIT is constitutively active, colocalization of both
proteins can be observed in the membrane area and by
coprecipitation. Interestingly, coprecipitation is abolished in
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FIGURE 7 | Myo1f knockdown does not affect SCF-dependent migration. (A) Western blot showing the Myo1f shRNAs tested. (B) Western blot showing Myo1f
knockdown and (C) membrane surface expression of KIT receptor in LAD2 mast cells silenced for Myo1f (Myo1f-shRNA) or non-target control (NT-shRNA) after
doxycycline induction (0.5µg/mL). (D) Percentage of migrated LAD2 mast cells silenced for Myo1f (Myo1f-shRNA) or non-target control (NT-shRNA) toward an SCF
gradient (100 ng/mL) with doxycycline induction (0.5µg/mL). The student’s t-test was used for the statistical analysis. In all migration assays, viability was tested in the
upper wells after the assay. Data are the mean of three independent experiments.
FIGURE 8 | β1 and β7 integrin expression are reduced as well as adhesion and migration to fibronectin in Myo1f knockdown mast cells. (A) Flow cytometry analysis
of β1 (CD29) expression on NT and Myo1f shRNA LAD2 cells, (B) β7 integrin expression in NT shRNA and Myo1f shRNA. NT shRNA is represented by an empty
black curve and Myo1f shRNA is represented by a filled gray curve. The mean of each group is represented in parentheses. (C) NT shRNA cells and Myo1f shRNA
LAD2 cells were assayed for adhesion in fibronectin-coated wells, stimulated with SCF (100 ng/mL) for 30min, and the percentage of adhesion was determined. (D)
NT shRNA and Myo1f shRNA LAD2 mast cells were assessed for migration for 4 h in fibronectin-coated Transwell chambers and then counted under optic
microscopy. Viability was tested in the upper wells after the assay. The student’s t-test (A,B) or ordinary one-way ANOVA test (C,D) was used for the statistical
analysis (*p < 0.05, **p < 0.01). The bar chart data correspond to the mean of at least three independent experiments.
the presence of the kinase inhibitor sunitinib, that causes
both molecules to distribute mostly in the cytoplasm. Overall,
we concluded that Myo1f links 3BP2 to actin cytoskeleton
after KIT stimulation.
Myo1f has been reported as key for neutrophil migration.
Indeed, Myo1f knockout mice showed increased susceptibility
to infection by Listeria monocytogenes due to an improper
neutrophil migration to the infection sites (14). The authors
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FIGURE 9 | 3BP2 silencing decreases β1 expression and significantly impairs
adhesion to fibronectin. (A) Flow cytometry analysis of β1 (CD29) expression
on NT and 3BP2 shRNA LAD2 cells, (B) β7 integrin expression in NT shRNA
and 3BP2 shRNA. NT shRNA is represented by an empty black curve and
3BP2 shRNA is represented by a filled gray curve. The mean of each group is
represented in parentheses. (C) NT shRNA cells and 3BP2 shRNA LAD2 cells
were assayed for adhesion in fibronectin-coated wells, stimulated with SCF
(100 ng/mL) for 30min, and the percentage of adhesion was determined. The
student’s t-test (A,B) or ordinary one-way ANOVA test (C) was used for the
statistical analysis (**p < 0.01). The bar chart data correspond to the mean of
at least three independent experiments.
reported that Myo1f prevents excessive exocytosis of β2
integrin-containing vesicles by regulating cortical F-actin or by
controlling the final step of exocytosis (14). This type of integrin
is dominant in integrin-mediated adhesion to the vascular
endothelium, a process that is crucial for neutrophil migration
to infected tissues (42, 43). Lately, Salvermoser and collaborators
demonstrated that Myo1f is crucial for the dynamics of
the deformation of the neutrophil nucleus and consequent
capacity of these cells to extravasate in vivo rather than for
integrin regulation (44). More recently, it has been shown
that Myo1f regulates integrin-αVβ3 inducing M1-polarization in
macrophages through PI3K/Akt/STAT signaling (45).
In our study, we explore the expression of several integrins
after Myo1f knockdown. Our data showed that Myo1f
knockdown decrease the cell surface expression of two integrin
β chains, β1 (CD29) and β7, which are critical for mast cell
adhesion and migration, usually coupled with the α4 chain. It has
also been determined that Fyn kinase plays a role in mediating
KIT/β1 integrin crosstalk in mast cells through Rac activation
to promote spreading, cytoskeletal remodeling and migration
(39, 40). Integrin α-4/β-1 (VLA-4) and α-4/β-7 are receptors for
fibronectin (46). Consequently, we found that Myo1f-silenced
cells have significantly reduced mast cell adhesion to fibronectin
upon SCF activation. Moreover, migration of Myo1f-silenced
mast cells was impaired, specifically on the integrin ligand
(fibronectin)-coated surface, which resembles the physiological
environment. Our results suggest that Myo1f may regulate
integrin trafficking in mast cells and thus possibly affects
integrin-vesicle exocytosis. Interestingly, we found that 3BP2 can
also regulate β1 expression, thus indicating that both molecules
are involved in that pathway, but cannot regulate β7 integrins,
thereby showing a selective cascade for both molecules. β2
integrin levels in LAD2 were almost undetectable (data not
shown), in line with the very low levels of β2 previously reported
in human mast cells (47). We cannot discard that Myo1f may
be acting in the integrin functionality as well. Integrins and
actin are coupled through a physical linkage, which provides
traction for migration (48). In that context, Myo1f would
provide a link with the actin cytoskeleton and the adaptor
protein 3BP2 delivering signals for adhesion to fibronectin and
further cell migration. More experiments are needed to define
the mechanism.
With respect to the role of Myo1f in the immune system,
the Myo1f gene has been found to be fused to the mixed
lineage leukemia (MLL) gene in acute monocytic leukemia (49).
The presence of the Vav1-Myo1f fusion protein (where the
C-terminal SH3 domain of Vav1 is replaced by the SH3 of
Myo1f) was recently reported in peripheral T-cell lymphomas
(PTLC), a heterogeneous group of non-Hodgkin lymphomas
frequently associated with poor prognosis. This supports a
possible role for the Myo1f SH3 domain in promoting the
activity of the Vav1-Myo1f oncoprotein (50, 51). Furthermore,
Myo1f has been proposed as a candidate gene for nonsyndromic
deafness (52).
In summary, we have defined a key role for 3BP2 in SCF-
dependent mast cell migration and identified a new partner,
Myo1f, which links the adaptor to the actin cytoskeleton
following KIT activation. This myosin regulates integrin-
dependent adhesion and migration.
Further investigation is needed to clarify the mechanisms of
Myo1f in the regulation of migration. The targeting of Myo1f
could serve as a tool to help shed light on cytoskeleton changes
to modulate mast cell function.
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